JP2021524476A - 設計された細菌組成物及びその使用 - Google Patents

設計された細菌組成物及びその使用 Download PDF

Info

Publication number
JP2021524476A
JP2021524476A JP2020565841A JP2020565841A JP2021524476A JP 2021524476 A JP2021524476 A JP 2021524476A JP 2020565841 A JP2020565841 A JP 2020565841A JP 2020565841 A JP2020565841 A JP 2020565841A JP 2021524476 A JP2021524476 A JP 2021524476A
Authority
JP
Japan
Prior art keywords
seq
composition
composition according
bacteria
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020565841A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524476A5 (https=
JPWO2019227085A5 (https=
Inventor
アスンシオン マルティネス，
アスンシオン マルティネス，
エドワード ジェイ． オブライエン，
エドワード ジェイ． オブライエン，
シェリー リン シモンズ，
シェリー リン シモンズ，
デビット クック，
デビット クック，
マシュー アール． ヘン，
マシュー アール． ヘン，
クリストファー ビー． フォード，
クリストファー ビー． フォード，
ディヴィヤ バラスブラマニアン，
ディヴィヤ バラスブラマニアン，
アンバー ピニャ，
アンバー ピニャ，
リヤン ディアオ，
リヤン ディアオ，
メーガン チェイフィー，
メーガン チェイフィー，
マリン ヴリック，
マリン ヴリック，
マドゥミタ ナンダクマール，
マドゥミタ ナンダクマール，
スモン ダッタ，
スモン ダッタ，
ラッタ ジャヤラマン，
ラッタ ジャヤラマン，
Original Assignee
セレス セラピューティクス インコーポレイテッド
セレス セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレス セラピューティクス インコーポレイテッド, セレス セラピューティクス インコーポレイテッド filed Critical セレス セラピューティクス インコーポレイテッド
Publication of JP2021524476A publication Critical patent/JP2021524476A/ja
Publication of JP2021524476A5 publication Critical patent/JP2021524476A5/ja
Publication of JPWO2019227085A5 publication Critical patent/JPWO2019227085A5/ja
Priority to JP2024060904A priority Critical patent/JP2024099549A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/308—Foods, ingredients or supplements having a functional effect on health having an effect on cancer prevention
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
JP2020565841A 2018-05-24 2019-05-24 設計された細菌組成物及びその使用 Pending JP2021524476A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024060904A JP2024099549A (ja) 2018-05-24 2024-04-04 設計された細菌組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862676236P 2018-05-24 2018-05-24
US62/676,236 2018-05-24
PCT/US2019/034069 WO2019227085A1 (en) 2018-05-24 2019-05-24 Designed bacterial compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024060904A Division JP2024099549A (ja) 2018-05-24 2024-04-04 設計された細菌組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021524476A true JP2021524476A (ja) 2021-09-13
JP2021524476A5 JP2021524476A5 (https=) 2022-06-01
JPWO2019227085A5 JPWO2019227085A5 (https=) 2022-06-01

Family

ID=68615645

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020565841A Pending JP2021524476A (ja) 2018-05-24 2019-05-24 設計された細菌組成物及びその使用
JP2024060904A Pending JP2024099549A (ja) 2018-05-24 2024-04-04 設計された細菌組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024060904A Pending JP2024099549A (ja) 2018-05-24 2024-04-04 設計された細菌組成物及びその使用

Country Status (10)

Country Link
US (2) US20210196766A1 (https=)
EP (1) EP3801065A4 (https=)
JP (2) JP2021524476A (https=)
KR (1) KR20210024481A (https=)
CN (1) CN112512342A (https=)
AU (1) AU2019275125A1 (https=)
BR (1) BR112020023933A2 (https=)
CA (1) CA3101184A1 (https=)
MX (1) MX2020012602A (https=)
WO (1) WO2019227085A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2967077A4 (en) 2013-03-15 2016-09-14 Seres Therapeutics Inc NETWORK-BASED MICROBIAL COMPOSITIONS AND METHOD
EP3444330B1 (en) * 2016-06-14 2025-08-20 HealthBiome, Inc. Strain of genus agathobaculum having effects of preventing or treating degenerative brain diseases, and use thereof
JP7168558B2 (ja) 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
EP3597202A1 (en) * 2018-07-20 2020-01-22 Maat Pharma Fecal microbiota composition, for use in reducing treatment-induced inflammation
WO2020037271A1 (en) 2018-08-17 2020-02-20 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
WO2021057985A1 (zh) * 2019-09-27 2021-04-01 成都中医药大学 检测粪钙卫蛋白含量的试剂在制备子宫病变筛查试剂盒中的用途
CA3159711A1 (en) * 2019-11-27 2021-06-03 Asuncion Martinez Designed bacterial compositions and uses thereof
CN116209750A (zh) * 2019-12-20 2023-06-02 西奈山伊坎医学院 用于治疗炎症性肠病的组合物和方法
IL271775A (en) * 2019-12-31 2021-06-30 Biomica Ltd Microbial consortium and uses thereof
WO2021163212A1 (en) 2020-02-10 2021-08-19 Native Microbials, Inc. Microbial compositions and methods of use for canine enteropathy and dysbiosis
CN115052609A (zh) * 2020-02-12 2022-09-13 苏黎世大学 一种治疗癌症的细菌组合物
JP2023517235A (ja) * 2020-03-10 2023-04-24 フェデレーション バイオ インコーポレイテッド 疾患の処置のための微生物コンソーシアム
GB202007452D0 (en) 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
US20230233620A1 (en) * 2020-05-21 2023-07-27 Chan Zuckerberg Biohub, Inc. High-complexity synthetic gut bacterial communities
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
KR102700146B1 (ko) * 2020-09-28 2024-08-28 씨제이바이오사이언스 주식회사 미생물을 포함하는 염증성 질환 진단 또는 치료용 조성물
WO2022159711A1 (en) * 2021-01-21 2022-07-28 Vedanta Biosciences, Inc. Compositions and methods for treating hepatic encephalopathy
WO2022178193A2 (en) * 2021-02-17 2022-08-25 Seres Therapeutics, Inc. Use of immunotherapy and microbiome modulation to treat cancer
WO2022236365A1 (en) * 2021-05-10 2022-11-17 Microba Ip Pty Ltd Compositions and methods for treating disease
NL2028324B1 (en) * 2021-05-28 2022-12-12 Caelus Pharmaceuticals B V Insulin-sensitizing agent and butyrate-producing bacterium
CN115806893B (zh) * 2021-09-13 2023-10-20 中国科学技术大学 普通拟杆菌及其组合物在辅助癌症免疫治疗中的应用
US20260027161A1 (en) * 2021-11-11 2026-01-29 Microba Ip Pty Ltd Bacterial strains for treating disease
CN114496279B (zh) * 2022-01-12 2022-08-30 广州保量医疗科技有限公司 菌群移植配型的排序方法、系统、计算机设备及存储介质
CN115852001A (zh) * 2022-11-23 2023-03-28 深圳海关动植物检验检疫技术中心 一种小麦病原菌检测方法及其应用
GB2627012A (en) * 2023-02-13 2024-08-14 Acad Medisch Ct Predictive biomarker of neonatal E.coli mediated sepsis
CN117797176B (zh) * 2024-03-01 2024-07-02 南京大学 双孢梭菌在制备治疗非酒精性脂肪性肝病药物中的应用和一种药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014088982A1 (en) * 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
WO2014121298A2 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract
WO2017008026A1 (en) * 2015-07-08 2017-01-12 Seres Therapeutics, Inc. Methods of treating colitis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004104175A2 (en) * 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
US8906668B2 (en) * 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20160271189A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
US11260083B2 (en) * 2016-03-15 2022-03-01 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
SG11201901726QA (en) * 2016-09-16 2019-03-28 Ubiome Inc Method and system for panel characterizations
JP7542946B2 (ja) * 2016-09-27 2024-09-02 ボード オブ リージェンツ， ザ ユニヴァーシティー オブ テキサス システム マイクロバイオームをモジュレートすることにより、免疫チェックポイント遮断療法を増強するための方法
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
AU2019393877A1 (en) * 2018-12-05 2021-06-17 Seres Therapeutics, Inc. Compositions for stabilizing bacteria and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014088982A1 (en) * 2012-12-07 2014-06-12 Albert Einstein College Of Medicine Of Yeshiva University Gut barrier dysfunction treatment and prevention
WO2014121298A2 (en) * 2013-02-04 2014-08-07 Seres Health, Inc. Methods of populating a gastrointestinal tract
WO2017008026A1 (en) * 2015-07-08 2017-01-12 Seres Therapeutics, Inc. Methods of treating colitis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MOAYYEDI P. ET AL., GASTROENTEROLOGY, vol. 149, JPN6023023445, 2015, pages 102 - 109, ISSN: 0005210904 *
PARAMSOTHY S. ET AL., LANCET, vol. 389, JPN6023023447, 2017, pages 1218 - 1228, ISSN: 0005210903 *

Also Published As

Publication number Publication date
US20210196766A1 (en) 2021-07-01
KR20210024481A (ko) 2021-03-05
US20250367242A1 (en) 2025-12-04
EP3801065A1 (en) 2021-04-14
AU2019275125A1 (en) 2021-01-21
BR112020023933A2 (pt) 2021-04-27
MX2020012602A (es) 2021-03-31
EP3801065A4 (en) 2022-11-02
CN112512342A (zh) 2021-03-16
CA3101184A1 (en) 2019-11-28
JP2024099549A (ja) 2024-07-25
WO2019227085A8 (en) 2021-03-18
WO2019227085A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
JP2021524476A (ja) 設計された細菌組成物及びその使用
US11723934B2 (en) Compositions and methods for the induction of CD8+ T-cells
JP2023505098A (ja) 設計された細菌組成物及びその使用
Miquel et al. Faecalibacterium prausnitzii and human intestinal health
US20200121738A1 (en) Methods and compositions relating to isolated and purified microbes
US9386793B2 (en) Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota
JP2020532515A (ja) マイクロバイオーム関連障害の処置のための方法および組成物
US20240000859A1 (en) Designed bacterial compositions for treating graft-versus-host-disease
JP2021519763A (ja) 炎症性腸疾患を治療するための組成物及び方法
RU2846926C2 (ru) Разработанные бактериальные композиции и их применение
RU2799556C2 (ru) Композиции и способы лечения воспалительных заболеваний кишечника

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231205